Market news

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Clover Health Investments (NASDAQ:CLOV) is positioning its Medicare Advantage business to benefit from industry pricing discipline, member retention and the maturation of member cohorts, Interim Chief Financial Officer Clay Thornton said at Jefferies’ Healthcare Services and Technology Conference in

Conrad Wai, CEO, Counterpart Health, on September 15, 2026, sold 300,000 shares in Clover Health Inv

A number of stocks fell in the morning session after bipartisan lawmakers introduced the Protecting Approved Care Act, legislation aimed at reforming prior authorization and payment rules in Medicare Advantage plans.

Humana listed Counterpart Health among the vendors for its provider-performance and quality programs.

Clover Health Investments (NASDAQ:CLOV) grew its share price by 8.53 percent on Thursday to finish at $4.71 apiece, as investors took heart from Deutsche Bank’s optimistic rating for its stock. In its initial coverage of the stock, the investment firm assigned a buy recommendation on shares of Clover Health Investments (NASDAQ:CLOV) alongside a price target […]

Shares of health insurance company Clover Health (NASDAQ:CLOV) jumped 8.5% in the afternoon session after Deutsche Bank initiated coverage on the company with a Buy rating and a $6.00 price target.

Detailed price information for Clover Health Investments Corp (CLOV-Q) from The Globe and Mail including charting and trades.

Clover Health Investments (CLOV) shares rose 8% on Thursday after Deutsche Bank initiated coverage o

On August 5, Clover Health Investments Corp. (NASDAQ:CLOV) reported second-quarter 2026 results that turned a year-ago loss into real profit. GAAP net income came in at $28 million, a $39 million swing from the $10.6 million loss posted in the same quarter last year. Medicare Advantage membership climbed to 157,309, up 48% year over year, […]

WILMINGTON, Del., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced its participation in the following investor conferences: Interim Chief Financial Officer, Clay Thornton, will present at the 2026 Jefferies Healthcare Services and Technology Conference on Tuesday, September 15, 2026, at 1:40 p.m. Eastern Time. A live webcast and replay of the presentation will be accessible from Clover Health's investo

Germany’s 10 year bond yield is near levels last seen in 2011, which shows how firmly markets are pricing in higher-for-longer interest rates. Higher yields often pressure richly valued large caps. That shifts more attention toward Financially Fit Penny Stocks, where entry prices are lower and balance sheets play a larger role. This article highlights three stocks from the screener that combine penny stock pricing with a focus on financial health. The three Financially Fit Penny Stocks in...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 28.9% gain over the past six months, beating the S&P 500 by 18 percentage points.

Let’s dig into the relative performance of Clover Health (NASDAQ:CLOV) and its peers as we unravel the now-completed Q2 health insurance providers earnings season.

Detailed price information for Clover Health Investments Corp (CLOV-Q) from The Globe and Mail including charting and trades.

Clover Health's current valuation ignores cash flow limits, MLR risk, CMS bonus uncertainty, and challenging software business. See why I rate CLOV stock a Sell.

Let’s dig into the relative performance of Cigna (NYSE:CI) and its peers as we unravel the now-completed Q2 health insurance providers earnings season.

Clover Health Investments has delivered a very strong 227.7% return over the past 3 years, yet the share price around US$4.49 now lines up with valuation checks that suggest the stock no longer looks obviously cheap or clearly expensive. With the broader metrics pointing to an overall high value score, the current level raises the question of whether the recent gains still leave enough room for further upside. Clover Health Investments' 227.7% share price gain over 3 years sets a high bar...

Clover Health Investments, Corp. has already reported its second-quarter 2026 results, posting revenue of US$743.17 million versus US$477.62 million a year earlier and moving from a net loss of US$10.58 million to net income of US$28 million. Alongside this shift to profitability, the company highlighted strong Medicare Advantage membership growth and benefits from its AI-powered Clover Assistant platform, which management views as central to supporting future operational and financial...

Clover Health’s second quarter results were met with a positive market reaction, driven by strong Medicare Advantage membership growth and improved profitability. Management credited the quarter’s performance to the expansion of its Clover Assistant AI platform and disciplined focus on core markets, particularly New Jersey and Georgia. CEO Andrew Toy emphasized that “better clinical care leads to stronger cohort economics,” pointing to the impact of maturing member cohorts under the company’s te

2026-08-13. The following slide deck was published by Clover Health Investments, Corp.

Clover Health Investments (NASDAQ:CLOV) is positioning its Medicare Advantage model around earlier identification and treatment of chronic conditions, Interim Chief Financial Officer Clay Thornton said during a Canaccord Genuity conference presentation. Thornton said the company’s goal is to equip

Health insurance company Clover Health (NASDAQ:CLOV) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 55.6% year on year to $743.2 million. The company’s full-year revenue guidance of $2.96 billion at the midpoint came in 1.7% above analysts’ estimates. Its GAAP profit of $0.05 per share was $0.02 above analysts’ consensus estimates.

Clover Health Investments (NASDAQ:CLOV) reported second-quarter results that showed continued Medicare Advantage membership growth alongside profitability, while raising its full-year 2026 outlook across its key financial measures. Chief Executive Officer Andrew Toy said the company views its Clove

Detailed price information for Clover Health Investments Corp (CLOV-Q) from The Globe and Mail including charting and trades.

After years of burning cash and testing investor patience, Clover Health just posted results that bulls have been waiting for. But with medical costs creeping up and the stock already priced for perfection, the real question is whether this milestone is a turning point or a trap.

Toy retains a $44.68 million direct stake after the non-discretionary sale triggered by RSU vesting. Remaining tranches vest quarterly through October 2028, signaling predictable future sell-to-cover activity.